Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433171 · ClinicalTrials.gov registry record
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 8
- Enrollment target
NCT02433171: Clinical Trial study, sponsored by Yale University.
NCT02433171 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02433171 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing lesions. These state-of-the-art imaging tools will be used in combination with standard magnetic resonance imaging (MRI), MR spectroscopy (MRS) and FDG-PET (fluorodeoxyglucose).
Interventions
- PROCEDURE Standard of Care FDG-PET Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06-27 |
Why NCT02433171 stopped before completion
NCT02433171 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care FDG-PET Imaging is the first listed.
NCT02433171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02433171 about?
NCT02433171 is a clinical study titled "Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery". The goal of this protocol is to evaluate the potential of PET imaging of amino acid transport and microglial activation to improve the differentiation of tumor recurrence and radiation necrosis in patients with brain metastases after treatment with stereotactic radiosurgery (SRS) who have re-growing...
What is the current status of trial NCT02433171?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2015-01. Estimated completion is 2017-06-27.
What interventions are being tested in trial NCT02433171?
The interventions under investigation include: Standard of Care FDG-PET Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02433171?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia